Market Access News | pharmaphorum

News

Lilly's Alzheimer's drug gets UK nod, but no NHS funding

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NI

News

Pfizer gets a leg up in RSV as FDA clears jab for all adults

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference

News

AZ, Ionis get CHMP backing for ATTR polyneuropathy drug

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines

News

Novo Nordisk closes on EU okay for haemophilia antibody

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia.

News

FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug

At its second attempt, Astellas has won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for certain gastric cancers.

News

AbbVie gets continuous Parkinson's drug over the line in US

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.

Lilly's Alzheimer's drug gets UK nod, but no NHS funding

Pfizer gets a leg up in RSV as FDA clears jab for all adults

AZ, Ionis get CHMP backing for ATTR polyneuropathy drug

Novo Nordisk closes on EU okay for haemophilia antibody

FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug

AbbVie gets continuous Parkinson's drug over the line in US

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks